Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Chemotherapy. Johns Hopkins Medical Institutions, Baltimore, Maryland, United States

Survival: 13.5 months
Toxicity Grade: 4
Treatments: Chemotherapy
Drugs: Emcyt
Country: United States
City/State/Province: Baltimore, Maryland
Hospital: Johns Hopkins Medical Institutions
Journal: Link
Date: 3/2002

Patients: This Phase II study involved 42 patients with androgen independent prostate cancer. The median age was 68 years. Sites of metastasis included bone, soft tissue, and lymph nodes. Prior therapies included: prostatectomy, radiotherapy, and hormonal therapy.

Treatment: The treatment consisted of the administration of two chemotherapy drugs docetaxel (taxotere) and estramustine (emcyt).

Toxicity: Grade 4 toxicities included leucopenia, neutropenia, and one patient developed atrial fibrillation with congestive heart failure. (This patient had no documented history of prior cardiac problems.)

Results: The median survival for all patients was 13.5 months.

Support: The study was supported by Aventis Pharmaceuticals. In addition, half of the studyís authors (3 of 6) are members of the Advisory Board and the Speakerís Bureau for Aventis. Aventis markets taxotere.

E-mail to a Friend Email Physician More Information